BillionToOne is trading 4.01% down at $91.91 on October 8, 2026; no clear company-specific catalyst has been identified.
- Its latest announcement, published October 7, reported favorable peer-reviewed findings for its Northstar Response cancer-monitoring assay.
- Broader pressure may be contributing as investors weigh higher oil prices, rising Treasury yields and geopolitical risk.
- Provided market-index moves are modest and do not independently confirm a market-wide selloff of more than 0.5% today, leaving the cause uncertain.